Abcellera Biologics Inc (ABCL)

$3.58 -0.14 (-3.76%)
Market Cap 1.11B
Revenue (ttm) 28.83M
Net Income (ttm) -162.86M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -564.90%
Debt to Equity Ratio 0.00
Volume 2,618,200
Avg Vol 4,154,670
Day's Range N/A - N/A
Shares Out 299.34M
Stochastic %K 52%
Beta 0.73
Analysts Strong Sell
Price Target $9.00

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research coll...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 559 9005
Address:
150 West 4th Ave, Vancouver, Canada
Stocktradesmoon
Stocktradesmoon Dec. 27 at 8:14 PM
$ABCL
0 · Reply
estatebuyersmia
estatebuyersmia Dec. 27 at 6:45 PM
$ABCL
0 · Reply
InfraredImp
InfraredImp Dec. 27 at 5:25 PM
$ABCL Sentiment hinges on whether execution can finally outpace expectations; cost controls have to translate into healthier margins — any stumble could quickly widen valuation discounts. Patience helps only if fundamentals keep strengthening.
1 · Reply
Stocktradesmoon
Stocktradesmoon Dec. 27 at 9:26 AM
$ABCL $ABCL. Support on the 50 week SMA after a bullish cross with the 100 week SMA.
0 · Reply
Stocktradesmoon
Stocktradesmoon Dec. 27 at 7:23 AM
$ABCL
0 · Reply
ChartVisionSphere
ChartVisionSphere Dec. 27 at 6:57 AM
$ABCL The backdrop favors measured delivery over aggressive expansion promises. Competitive advantages must begin to appear in core metrics. Any deterioration in traction could reset expectations abruptly. Momentum becomes sustainable only when delivery keeps pace.
0 · Reply
Stocktradesmoon
Stocktradesmoon Dec. 27 at 1:54 AM
$ABCL 😉👀 15,000 followers. Do you understand what we can accomplish with a founder led 1B dollar market cap biotech stock with 700M+ in cash and no dilution if we all buy it and bull post daily about it with the most obscene and wild narrative that you can come up with? Greatness. $ABCL
1 · Reply
Ed_Ng
Ed_Ng Dec. 26 at 8:02 PM
$ABCL reason to avoid ABCL stock: scam!
1 · Reply
Stocktradesmoon
Stocktradesmoon Dec. 26 at 5:53 PM
$ABCL $ABCL $JNJ Clearing the way for $ABCL to dominate treatment of eczema if and when its antibody successfully emerges from clinical trials: https://www.cnbc.com/2025/12/26/johnson-johnson-halts-mid-stage-trial-of-experimental-eczema-drug.html
1 · Reply
estatebuyersmia
estatebuyersmia Dec. 26 at 4:51 PM
$ABCL REASON TO OWN ABCL
0 · Reply
Latest News on ABCL
AbCellera and Bruker Reach Global Settlement of Patent Litigation

Dec 18, 2025, 9:00 AM EST - 9 days ago

AbCellera and Bruker Reach Global Settlement of Patent Litigation

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Dec 8, 2025, 4:05 PM EST - 19 days ago

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

AbCellera Biologics Inc. (ABCL) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Dec 8, 2025, 1:37 PM EST - 19 days ago

AbCellera Biologics Inc. (ABCL) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

AbCellera Biologics Inc. (ABCL) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 22, 2025, 12:23 AM EST - 5 weeks ago

AbCellera Biologics Inc. (ABCL) Presents at Jefferies London Healthcare Conference 2025 Transcript

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 10, 2025, 9:00 AM EST - 6 weeks ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

AbCellera Biologics Inc. (ABCL) Q3 2025 Earnings Call Transcript

Nov 7, 2025, 7:16 PM EST - 7 weeks ago

AbCellera Biologics Inc. (ABCL) Q3 2025 Earnings Call Transcript

AbCellera Reports Q3 2025 Business Results

Nov 6, 2025, 4:05 PM EST - 7 weeks ago

AbCellera Reports Q3 2025 Business Results

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Oct 7, 2025, 4:05 PM EDT - 2 months ago

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

AbCellera Biologics: Entering Growth Phase After A Pause

Oct 6, 2025, 7:35 AM EDT - 2 months ago

AbCellera Biologics: Entering Growth Phase After A Pause

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

Sep 29, 2025, 4:05 PM EDT - 3 months ago

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 10, 2025, 9:07 AM EDT - 3 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 27, 2025, 9:00 AM EDT - 4 months ago

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

AbCellera to Participate at Upcoming Investor Conferences in September

Aug 12, 2025, 4:05 PM EDT - 4 months ago

AbCellera to Participate at Upcoming Investor Conferences in September

AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 7:48 PM EDT - 5 months ago

AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call Transcript

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Aug 7, 2025, 4:05 PM EDT - 5 months ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 7, 2025, 4:05 PM EDT - 6 months ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 30, 2025, 1:00 PM EDT - 7 months ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 14, 2025, 5:00 PM EDT - 8 months ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 12, 2025, 3:30 PM EDT - 8 months ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 9, 2025, 7:30 PM EDT - 8 months ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

AbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call Transcript

May 8, 2025, 10:33 PM EDT - 8 months ago

AbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call Transcript

AbCellera Reports Q1 2025 Business Results

May 8, 2025, 4:05 PM EDT - 8 months ago

AbCellera Reports Q1 2025 Business Results

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 29, 2025, 3:00 PM EDT - 8 months ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 8, 2025, 4:05 PM EDT - 9 months ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 3, 2025, 4:05 PM EDT - 9 months ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Mar 25, 2025, 4:30 PM EDT - 9 months ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 11:26 PM EST - 10 months ago

AbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call Transcript

AbCellera Reports Full Year 2024 Business Results

Feb 27, 2025, 4:05 PM EST - 10 months ago

AbCellera Reports Full Year 2024 Business Results

AbCellera to Participate at Upcoming Investor Conferences in March

Feb 11, 2025, 4:05 PM EST - 11 months ago

AbCellera to Participate at Upcoming Investor Conferences in March

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 21, 2025, 4:05 PM EST - 1 year ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Jan 13, 2025, 9:00 AM EST - 1 year ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

AbCellera Biologics: Still A Concept Stock

Dec 23, 2024, 4:39 PM EST - 1 year ago

AbCellera Biologics: Still A Concept Stock

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 21, 2024, 4:05 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in December and January

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 7, 2024, 10:05 AM EST - 1 year ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

AbCellera Biologics Inc. (ABCL) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 7:22 PM EST - 1 year ago

AbCellera Biologics Inc. (ABCL) Q3 2024 Earnings Call Transcript

AbCellera Reports Q3 2024 Business Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results

AbCellera to Present at Upcoming Investor Conferences in November 2024

Oct 22, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in November 2024

AbCellera: A Platform To Pipeline Transition

Oct 14, 2024, 12:04 PM EDT - 1 year ago

AbCellera: A Platform To Pipeline Transition

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

Oct 4, 2024, 9:00 AM EDT - 1 year ago

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

Sep 26, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

AbCellera to Present at Upcoming Investor Conferences in September

Aug 29, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in September

AbCellera: A Waiting Game With High Uncertainty

Aug 23, 2024, 4:43 AM EDT - 1 year ago

AbCellera: A Waiting Game With High Uncertainty

This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Aug 20, 2024, 9:45 AM EDT - 1 year ago

This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

GLOB AVDX LRN PGRU

AbCellera Reports Q2 2024 Business Results

Aug 6, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2024 Business Results

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

Jul 31, 2024, 9:00 AM EDT - 1 year ago

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

Jun 25, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

May 28, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

AbCellera Biologics Inc. (ABCL) Q1 2024 Earnings Call Transcript

May 7, 2024, 11:00 PM EDT - 1 year ago

AbCellera Biologics Inc. (ABCL) Q1 2024 Earnings Call Transcript

AbCellera Reports Q1 2024 Business Results

May 7, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2024 Business Results

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

May 1, 2024, 9:00 AM EDT - 1 year ago

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

Stocktradesmoon
Stocktradesmoon Dec. 27 at 8:14 PM
$ABCL
0 · Reply
estatebuyersmia
estatebuyersmia Dec. 27 at 6:45 PM
$ABCL
0 · Reply
InfraredImp
InfraredImp Dec. 27 at 5:25 PM
$ABCL Sentiment hinges on whether execution can finally outpace expectations; cost controls have to translate into healthier margins — any stumble could quickly widen valuation discounts. Patience helps only if fundamentals keep strengthening.
1 · Reply
Stocktradesmoon
Stocktradesmoon Dec. 27 at 9:26 AM
$ABCL $ABCL. Support on the 50 week SMA after a bullish cross with the 100 week SMA.
0 · Reply
Stocktradesmoon
Stocktradesmoon Dec. 27 at 7:23 AM
$ABCL
0 · Reply
ChartVisionSphere
ChartVisionSphere Dec. 27 at 6:57 AM
$ABCL The backdrop favors measured delivery over aggressive expansion promises. Competitive advantages must begin to appear in core metrics. Any deterioration in traction could reset expectations abruptly. Momentum becomes sustainable only when delivery keeps pace.
0 · Reply
Stocktradesmoon
Stocktradesmoon Dec. 27 at 1:54 AM
$ABCL 😉👀 15,000 followers. Do you understand what we can accomplish with a founder led 1B dollar market cap biotech stock with 700M+ in cash and no dilution if we all buy it and bull post daily about it with the most obscene and wild narrative that you can come up with? Greatness. $ABCL
1 · Reply
Ed_Ng
Ed_Ng Dec. 26 at 8:02 PM
$ABCL reason to avoid ABCL stock: scam!
1 · Reply
Stocktradesmoon
Stocktradesmoon Dec. 26 at 5:53 PM
$ABCL $ABCL $JNJ Clearing the way for $ABCL to dominate treatment of eczema if and when its antibody successfully emerges from clinical trials: https://www.cnbc.com/2025/12/26/johnson-johnson-halts-mid-stage-trial-of-experimental-eczema-drug.html
1 · Reply
estatebuyersmia
estatebuyersmia Dec. 26 at 4:51 PM
$ABCL REASON TO OWN ABCL
0 · Reply
estatebuyersmia
estatebuyersmia Dec. 26 at 4:44 PM
$ABCL HANSEN IS A GENIUS.....
0 · Reply
Ed_Ng
Ed_Ng Dec. 26 at 2:38 PM
$ABCL nice
0 · Reply
Stocktradesmoon
Stocktradesmoon Dec. 26 at 4:34 AM
$ABCL
0 · Reply
1iquid
1iquid Dec. 25 at 2:08 PM
💎 Liquid® Live Actionable Trade Asset: $ABCL Contracts: $ABCL January 15, 2027 $4 Calls Scale in: $1.27- $1.55 Scale out: $4.94-$8.48 Profit Potential : 253% ROI Blended Join 💎 Here: https://1iquid.com
0 · Reply
UncleTomFlorida
UncleTomFlorida Dec. 25 at 12:47 PM
$ABCL
0 · Reply
UncleTomFlorida
UncleTomFlorida Dec. 25 at 12:09 AM
$ABCL I reached my accumulation goal today. Was hoping for the dip continuing. I will niw have to . Chase different stox before the end of the year.
0 · Reply
UncleTomFlorida
UncleTomFlorida Dec. 25 at 12:07 AM
$ABCL $RKLB
0 · Reply
UncleTomFlorida
UncleTomFlorida Dec. 25 at 12:06 AM
$ABCL
0 · Reply
Stocktradesmoon
Stocktradesmoon Dec. 24 at 11:20 PM
$ABCL
0 · Reply
1Investor9
1Investor9 Dec. 24 at 10:57 PM
I don’t know if Abcellera will change lives but I do know that $ABCL the stock will change yours. You gonna buy at $3.70 like $RKLB or chase at $79 down the line? Up to you, tiger. Biotech will be the biggest boom in history. 1 billion market cap, 750m in cash. Let’s play
0 · Reply
estatebuyersmia
estatebuyersmia Dec. 24 at 7:29 PM
$ABCL 2026 WILL BE A PHENOMENAL YEAR FOR BIOTECH... WATCH
0 · Reply
estatebuyersmia
estatebuyersmia Dec. 24 at 6:23 PM
$ABCL MERRY CHRISTMAS TO ALL THE BULLS AND SCREW THE BEARS...
0 · Reply